---
title: "Supriya Lifescience Ltd (SUPRIYA) — Share Price, Financials & Analysis"
symbol: "SUPRIYA"
company: "Supriya Lifescience Ltd"
canonical: "https://tapetide.com/stocks/SUPRIYA"
isin: "INE07RO01027"
nse_symbol: "SUPRIYA"
bse_code: "543434"
sector: "Healthcare"
industry: "Pharmaceuticals & Biotechnology"
market_cap_cr: 7234.2
generated_at: "2026-09-13T19:22:21.124Z"
---

# Supriya Lifescience Ltd (SUPRIYA)

Canonical page: https://tapetide.com/stocks/SUPRIYA

## Company

- **NSE Symbol:** SUPRIYA
- **BSE Code:** 543434
- **ISIN:** INE07RO01027
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals & Biotechnology
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2021-12-28
- **Face Value:** ₹2
- **F&O Eligible:** No
- **Website:** supriyalifescience.com

## About

Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic.[1]

## Latest Price

- **Price:** ₹901.75
- **Change:** -15.7 (-1.71%)
- **Open:** ₹915
- **Day High:** ₹915.3
- **Day Low:** ₹891.25
- **Previous Close:** ₹917.45
- **Volume:** 208583
- **As Of:** 2026-09-11T10:27:27+00:00

## Key Fundamentals

Observed at 2026-09-11T04:42:30.632677Z.

- **Market Cap:** ₹7234.2 Cr
- **Classification:** Microcap
- **P/E (reported):** 37.3
- **P/E (TTM):** 36.58
- **EPS (TTM):** ₹24.65
- **EPS (reported):** ₹16.8
- **Book Value:** ₹148.82
- **Price to Book:** 6.17
- **Dividend Yield:** 0.11%
- **ROE:** 17.46%
- **ROCE:** 22.38%
- **Debt to Equity:** 0
- **Revenue (yearly):** ₹839.4 Cr
- **Net Income:** ₹209.1 Cr
- **EBITDA:** ₹305.5 Cr
- **52-Week High:** ₹1085
- **52-Week Low:** ₹545.5
- **RSI (14):** 66.43

## Tapetide Score

- **Score:** 58 / 100
- **Score date:** 2026-09-04
- **Archetype:** No Dominant Pattern
- **What it means:** The three pillars do not combine into a recognisable pattern. Read them individually rather than looking for one story — the lack of a pattern is itself the finding.
- **Pillar profile:** Quality: Average · Valuation: Expensive · Momentum: Flat
- **Percentile:** 81.3 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 83.65 | 9% |
| growth | 76.2 | 9% |
| momentum | 59.34 | 12% |
| ownership | 56.73 | 24% |
| quality | 56.87 | 22% |
| valuation | 45.42 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company is almost debt free.
- Company is expected to give good quarter

### Weaknesses

- Debtor days have increased from 79.6 to 96.8 days.

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 12.81% | 63.95% | 280.68% |
| ebitda margin growth | -50.45% | -4.99% | 15.19% | -11.67% |
| net income growth | -67.65% | 11.22% | 32% | 11% |
| revenue growth | -31.29% | 18.84% | 22% | 16% |
| roce | — | -7.83% | 12.63% | 23.46% |
| roe | — | -7.42% | 16.98% | -29.2% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 140 | 140 | 158 | 161 | 166 | 186 | 184 | 145 | 200 | 206 | 277 | 190 |
| Expenses | 108 | 99 | 103 | 98 | 101 | 120 | 117 | 93 | 127 | 134 | 179 | 142 |
| Operating Profit | 32 | 41 | 56 | 63 | 65 | 66 | 68 | 52 | 73 | 72 | 98 | 47 |
| OPM % | 23 | 30 | 35 | 39 | 39 | 36 | 37 | 36 | 36 | 35 | 35 | 25 |
| Other Income | 2 | 3 | 2 | 2 | 3 | 2 | 3 | 3 | 3 | 2 | 3 | 3 |
| Interest | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| Depreciation | 4 | 4 | 4 | 5 | 5 | 5 | 6 | 6 | 7 | 7 | 8 | 9 |
| Profit before tax | 30 | 40 | 53 | 60 | 62 | 63 | 64 | 47 | 68 | 67 | 92 | 41 |
| Tax % | 20 | 26 | 31 | 25 | 26 | 25 | 21 | 27 | 26 | 26 | 19 | 41 |
| Net Profit | 24 | 30 | 37 | 45 | 46 | 47 | 50 | 35 | 50 | 50 | 74 | 24 |
| EPS in Rs | 2.97 | 3.7 | 4.59 | 5.55 | 5.73 | 5.81 | 6.26 | 4.32 | 6.27 | 6.17 | 9.22 | 2.99 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 213 | 278 | 312 | 391 | 530 | 461 | 570 | 696 | 828 | 873 |
| Expenses | 191 | 213 | 213 | 218 | 316 | 332 | 394 | 436 | 533 | 583 |
| Operating Profit | 22 | 65 | 98 | 173 | 214 | 129 | 176 | 261 | 295 | 290 |
| OPM % | 10 | 23 | 32 | 44 | 40 | 28 | 31 | 37 | 36 | 33 |
| Other Income | 9 | 8 | 11 | 5 | 8 | 9 | 11 | 10 | 11 | 11 |
| Interest | 11 | 10 | 7 | 4 | 4 | 3 | 5 | 2 | 3 | 2 |
| Depreciation | 5 | 5 | 6 | 7 | 10 | 12 | 16 | 20 | 28 | 31 |
| Profit before tax | 14 | 57 | 96 | 167 | 207 | 123 | 166 | 248 | 275 | 268 |
| Tax % | 40 | 31 | 24 | 26 | 27 | 27 | 28 | 24 | 24 | — |
| Net Profit | 9 | 39 | 73 | 124 | 152 | 90 | 119 | 188 | 209 | 198 |
| EPS in Rs | 5.96 | 26.93 | 50.11 | 16.89 | 18.86 | 11.17 | 14.8 | 23.35 | 25.98 | 24.65 |
| Dividend Payout % | 0 | 0 | 20 | 3 | 3 | 5 | 5 | 4 | 4 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 15 | 15 | 15 | 15 | 15 | 16 | 16 | 16 | 16 | 16 |
| Reserves | 31 | 40 | 79 | 134 | 254 | 600 | 683 | 799 | 981 | 1182 |
| Borrowings | 140 | 130 | 90 | 82 | 72 | 27 | 22 | 5 | 5 | 5 |
| Other Liabilities | 55 | 60 | 69 | 105 | 105 | 92 | 98 | 101 | 115 | 154 |
| Total Liabilities | 241 | 245 | 253 | 336 | 445 | 735 | 820 | 921 | 1117 | 1357 |
| Fixed Assets | 89 | 91 | 85 | 99 | 100 | 190 | 262 | 310 | 453 | 689 |
| CWIP | 36 | 34 | 35 | 40 | 79 | 43 | 68 | 149 | 148 | 36 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 25 | 64 | 63 | 99 |
| Other Assets | 117 | 120 | 133 | 197 | 267 | 502 | 466 | 399 | 453 | 534 |
| Total Assets | 241 | 245 | 253 | 336 | 445 | 735 | 820 | 921 | 1117 | 1357 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 27 | 28 | 49 | 117 | 76 | 49 | 64 | 113 | 165 | 186 |
| Cash from Investing Activity | -27 | -5 | 5 | -25 | -47 | -60 | -124 | -174 | -152 | -176 |
| Cash from Financing Activity | -2 | -20 | -50 | -29 | -15 | 150 | -10 | -22 | -8 | -10 |
| Net Cash Flow | -2 | 3 | 4 | 62 | 15 | 139 | -70 | -83 | 4 | 0 |
| Free Cash Flow | 0 | 23 | 54 | 92 | 29 | -11 | -44 | -32 | 2 | 34 |
| CFO/OP | 158 | 141 | 97 | 146 | 61 | 51 | 73 | 86 | 86 | 84 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 99 | 92 | 79 | 60 | 69 | 79 | 67 | 71 | 70 | 97 |
| Inventory Days | 113 | 85 | 77 | 130 | 206 | 172 | 234 | 140 | 205 | 229 |
| Days Payable | 121 | 112 | 110 | 130 | 145 | 91 | 130 | 98 | 129 | 159 |
| Cash Conversion Cycle | 91 | 64 | 45 | 61 | 130 | 160 | 171 | 114 | 146 | 167 |
| Working Capital Days | -69 | -50 | -5 | -40 | 28 | 117 | 168 | 157 | 144 | 147 |
| ROCE % | — | 14 | 37 | 50 | 60 | 43 | 19 | 22 | 27 | 25 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 68.3% | 68.3% | 68.3% | 68.3% | 68.3% | 68.3% | 68.3% | 68.3% | 68.3% | 68.3% | 68.3% | 68.3% |
| FIIs | 5.34% | 4.56% | 5.36% | 4.95% | 6.03% | 6.52% | 7.19% | 6.78% | 5.46% | 5.2% | 5.16% | 6.19% |
| DIIs | 7.17% | 3.85% | 5.3% | 5.48% | 5.45% | 4.92% | 4.26% | 4.86% | 5.22% | 5.01% | 5.7% | 5.3% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 16.1% | 17.5% | 17.06% | 17.19% | 0% | 16.28% | 16.4% | 16.39% | 16.77% | 16.66% | 16.22% | 15.98% |
| Others | 3.09% | 5.79% | 3.98% | 4.08% | 20.23% | 3.98% | 3.85% | 3.67% | 4.25% | 4.83% | 4.63% | 4.23% |
| No. of Shareholders | 92991 | 95929 | 87980 | 89621 | 85328 | 89394 | 91051 | 91928 | 87912 | 85099 | 81161 | 82082 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Buy
- **Buy / Neutral / Sell:** 12 / 4 / 3

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 869.35 | Buy |
| EMA (10) | 877.79 | Buy |
| SMA (20) | 831.76 | Buy |
| EMA (20) | 857.74 | Buy |
| SMA (50) | 847.25 | Buy |
| EMA (50) | 849.3 | Buy |
| SMA (100) | 839.75 | Buy |
| EMA (100) | 826.01 | Buy |
| SMA (200) | 760.77 | Buy |
| EMA (200) | 785.2 | Buy |

### Oscillators — summary: **Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 61.7 | Neutral |
| MACD (12,26,9) | 17.22 | Buy |
| Stochastic (14,3,3) | 87.09 | Sell |
| ADX (14) | 23.22 | Neutral |
| Williams %R (14) | -19.77 | Sell |
| ATR (14) | 32.95 | High Volatility |
| ROC (12) | 15.35 | Buy |
| Stoch RSI (14) | 83.02 | Sell |
| UO (7,14,28) | 56.15 | Neutral |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 30 Apr - April 30, 2026 disclosure says Supriya Lifescience is not a large corporate; outstanding borrowing nil, highest rating A+. | [Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 30 Apr - April 30, 2026 disclosure says Supriya Lifescience is not a large corporate; outstanding borrowing nil, highest rating A+.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/47da0937-4278-47ed-b6bf-9c5908629c4e.pdf) |
| 30 Apr - April 30, 2026 disclosure says Supriya Lifescience is not a large corporate; outstanding borrowing nil, highest rating A+. | [Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 30 Apr - April 30, 2026 disclosure says Supriya Lifescience is not a large corporate; outstanding borrowing nil, highest rating A+.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/47da0937-4278-47ed-b6bf-9c5908629c4e.pdf) |
| 24 Mar - Two independent directors' five-year terms ended March 24, 2026; board committees reconstituted. | [Announcement under Regulation 30 (LODR)-Change in Directorate 24 Mar - Two independent directors' five-year terms ended March 24, 2026; board committees reconstituted.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/58fbadfb-2d3b-4dcd-85a7-9896dab77c97.pdf) |
| 22 Apr - USFDA inspection at Lote facility ended with one minor Form 483 observation; EIR received with VAI on April 22, 2026. | [Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 - Update On Inspection By United States Food & Drug Administration (USFDA) 22 Apr - USFDA inspection at Lote facility ended with one minor Form 483 observation; EIR received with VAI on April 22, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/a525f582-05bc-4151-a604-30d310e1db5b.pdf) |
| 17 Feb - Transcript of the Earnings Call for the Unaudited Financial Results for quarter and nine months ended December 31, 2025, is enclosed herewith. Kindly take the … | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript 17 Feb - Transcript of the Earnings Call for the Unaudited Financial Results for quarter and nine months ended December 31, 2025, is enclosed herewith. Kindly take the …](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5c86e735-7f0f-475f-a99f-f79ab0ec8089.pdf) |
| 15h - USFDA inspection at Lote facility ended with one minor Form 483 observation; EIR received with VAI on April 22, 2026. | [Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 - Update On Inspection By United States Food & Drug Administration (USFDA) 15h - USFDA inspection at Lote facility ended with one minor Form 483 observation; EIR received with VAI on April 22, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/a525f582-05bc-4151-a604-30d310e1db5b.pdf) |
| 11 Sep - Intimation of Investor/ Analyst Call is enclosed herewith. Kindly take the same on record. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 11 Sep - Intimation of Investor/ Analyst Call is enclosed herewith. Kindly take the same on record.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9a7c1aef-8a47-4e29-8477-2347f8e82ca4.pdf) |
| 11 Mar - Newspaper Extract of Postal Ballot Notice dispatched to Shareholders. | [Announcement under Regulation 30 (LODR)-Newspaper Publication 11 Mar - Newspaper Extract of Postal Ballot Notice dispatched to Shareholders.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/994849ad-f598-40d9-9c4b-432eaa23f493.pdf) |
| 11 Apr - Postal ballot passed appointing Manish Panchal, Kothandaraman Hari, and reappointing Neelam Arora as independent directors. | [Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot 11 Apr - Postal ballot passed appointing Manish Panchal, Kothandaraman Hari, and reappointing Neelam Arora as independent directors.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f5311e49-50e6-4cff-9852-efd578f76c78.pdf) |
| 11 Apr - Postal ballot passed appointing Manish Panchal, Kothandaraman Hari, and reappointing Neelam Arora as independent directors. | [Shareholder Meeting / Postal Ballot-Scrutinizer"s Report 11 Apr - Postal ballot passed appointing Manish Panchal, Kothandaraman Hari, and reappointing Neelam Arora as independent directors.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/e1a9a716-a31e-412f-b47e-eba8248a06c5.pdf) |

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-02 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9a876d2f-cfce-4e47-b35f-b4e36e7ab944.pdf) |
| 2026-09-02 | [Announcement Under Regulation 30 Of SEBI (LODR) Regulations 2015.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0cb99471-7467-43d7-a966-036c360f886f.pdf) |
| 2026-09-02 | [Intimation Under Regulation 30 Regarding Letter Dispatched To The Shareholders Of The Company](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=33752d7e-2b08-4795-ad01-e802269ae601.pdf) |
| 2026-09-01 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a7c70a8a-2960-402e-a915-992a8d96f2e5.pdf) |
| 2026-09-01 | [Notice Of 18Th Annual General Meeting Of The Company.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7f3d610b-0415-4a12-bc21-f29465fe2202.pdf) |
| 2026-09-01 | [Business Responsibility and Sustainability Reporting (BRSR)](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2616d8cf-82d6-4f95-909c-fd9f02069c8f.pdf) |
| 2026-08-27 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f7479c7d-4f0f-4eda-917e-ec901b2e5287.pdf) |
| 2026-08-26 | [Record Date For Determining Members Eligible To Receive Dividend For The Financial Year 2025-26.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dcbd6012-fc9f-4254-9965-4a3235b96287.pdf) |
| 2026-08-22 | [Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=066bbbf2-b3ea-4ab8-a9cd-41aea7315731.pdf) |
| 2026-08-22 | [Shareholder Meeting / Postal Ballot-Scrutinizer"s Report](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4ae080fa-0393-4b5a-90f4-1d08de608a8c.pdf) |

### Earnings Call Transcripts

| Date | Document |
| --- | --- |
| 2026-08-18 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b59fa84a-5cfe-486b-95bc-c0ad1bda1d2a.pdf) |
| 2026-06-02 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a4736b39-fb57-499b-8e41-e3e4d5d166ad.pdf) |
| 2026-02-17 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5c86e735-7f0f-475f-a99f-f79ab0ec8089.pdf) |
| 2025-11-18 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ea39e12f-cd9e-4ee7-8104-4c8b6a6b34ce.pdf) |
| 2025-08-19 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=98638ed4-8a32-42e3-8bb4-6fe69b1ae22c.pdf) |
| 2025-05-31 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=62c18ff5-eee2-4b37-8b91-6b41787e6bb4.pdf) |
| 2025-01-31 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2d9a141a-aa89-4d05-aa94-5e54666c355c.pdf) |
| 2024-11-04 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=48bdf40f-f558-438d-96c9-3206b57c3bc5.pdf) |
| 2024-08-19 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f79df80d-ff2b-40da-9359-0faabfb7f2a5.pdf) |
| 2024-06-05 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=64845815-5ac2-4c3c-b20b-438ab9f17849.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-08-13 | [Unaudited Financial Results For The Quarter Ended June 30 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3605d5d1-aebe-400e-9421-d16bd7c6aff5.pdf) |
| 2026-05-27 | [Audited Financial Results For Quarter And Year Ended March 31 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e0840e7b-b870-4080-8bd0-d0ba29abef6e.pdf) |
| 2026-02-09 | [Financial Result Quarter Ended On December 31 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7016a6c6-13cd-4728-8112-652184e7d3e3.pdf) |
| 2025-11-12 | [Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c9f31753-611c-4ddd-80c8-a79d0253522e.pdf) |
| 2025-08-13 | [Unaudited Financial Result For The Quarter Ended On June 30 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8d428a80-9f64-46c6-89ac-a37801df9724.pdf) |
| 2025-05-27 | [Audited Financial Result For Quarter And Year Ended On March 31 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f6a54abc-a2db-4bbc-9afa-ef4b859c5994.pdf) |
| 2025-01-24 | [Unaudited Financial Results For The Quarter And Nine Month Ended December 31 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=26b06b6d-9ea1-4192-98f2-ab751ff84f68.pdf) |
| 2024-10-28 | [Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=915b66eb-a9ab-40a4-bfe4-5fa7a8828e05.pdf) |
| 2024-08-10 | [Unaudited Financial Results For The Quarter Ended June 30, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=279db8d9-d747-4564-9735-26f9906d6fde.pdf) |
| 2024-05-28 | [Audited Financial Results For The Quarter And Year Ended March 31, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=78ede806-162e-4d25-b43f-333aa04651dd.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2026-08-13 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f6547e67-7979-4491-8dfe-9bd488977760.pdf) |
| 2026-05-27 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=18a6f685-563c-48fa-a7ea-8d95f3ff8589.pdf) |
| 2026-02-09 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f43b1341-6a7f-425c-80a9-4b8b6887590c.pdf) |
| 2025-11-12 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=980590cc-304e-4c6f-a027-74dbbb48480e.pdf) |
| 2025-08-13 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=585d7f44-4faf-41d5-ae35-e95cfbb287a2.pdf) |
| 2025-05-27 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=50d4116b-de86-4332-8c93-b9b8989dad88.pdf) |
| 2025-01-24 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7c01a1a9-c171-4e0f-98a4-19c447700df9.pdf) |
| 2024-10-28 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bc464cb2-a0e1-4f6b-8fd0-0eace312c6aa.pdf) |
| 2024-08-10 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=77f606ae-2674-4096-b94c-b5bda1294605.pdf) |
| 2024-05-28 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=50f334bb-a063-408b-a5ad-e08a42b4d7d3.pdf) |

### Earnings Call Recordings

| Date | Document |
| --- | --- |
| 2026-05-28 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fe5ada3c-c08e-4588-a8e1-1a7e57aa9032.pdf) |
| 2026-02-10 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9090e14f-1642-45a2-b13d-218a950f9f0a.pdf) |
| 2025-11-13 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=18653b41-e7e7-4e7b-ad52-76255c30bdb9.pdf) |
| 2025-08-14 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e84c001f-2ff2-4023-9b5b-ac3a9933b6cd.pdf) |
| 2025-05-28 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9d3b53f7-2555-4fb0-b5cd-b65668e75c3e.pdf) |
| 2024-05-29 | [Audio Recording Of Earning Call](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8817fa8d-dc3e-4788-8432-271ba5010e25.pdf) |
| 2023-08-04 | [Audio Recording Of Earnings Call](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ee21b016-f030-46d5-a5a1-a25612a1d16c.pdf) |
| 2023-05-29 | [Audio Recording Of Earnings Call](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=aa3e8174-b7b8-4792-9fed-d6e4a2fb0751.pdf) |
| 2023-02-15 | [Audio Recording Of Earnings Call](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=55626bc7-9a1f-4339-bc11-faf53d2904e8.pdf) |
| 2022-11-11 | [Audio Recording Of Earnings Call](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=89fad0ce-8afa-48a3-bb8b-38bf2c17f2a7.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ea39e12f-cd9e-4ee7-8104-4c8b6a6b34ce.pdf) |
| Nov 2024 | [Concall - Nov 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/48bdf40f-f558-438d-96c9-3206b57c3bc5.pdf) |
| Nov 2023 | [Concall - Nov 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5b7c5a16-3471-4932-a4c0-8f5ab29ef970.pdf) |
| Nov 2022 | [Concall - Nov 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b885104f-c5fc-4c36-898d-f4fd9e7d1fab.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/18a6f685-563c-48fa-a7ea-8d95f3ff8589.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/18a6f685-563c-48fa-a7ea-8d95f3ff8589.pdf) |
| May 2022 | [Concall - May 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/233dd6f0-bae1-4a8f-bb7c-0b68950be365.pdf) |
| May 2022 | [Concall - May 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/1d3d9594-3217-4860-aab2-a89d8198f7cd.pdf) |
| Jun 2024 | [Concall - Jun 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/64845815-5ac2-4c3c-b20b-438ab9f17849.pdf) |
| Jun 2023 | [Concall - Jun 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4883bda2-246a-4207-aedb-0394f02dc9ed.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Annual Report 2022 from nse](https://archives.nseindia.com/annual_reports/AR_20786_SUPRIYA_2021_2022_23082022134729_08232022140002.zip) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2acb789e-8958-4c5d-8131-d0677177f399.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ce151741-396c-411a-8399-f36911dcf9a7.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/04140113-39f5-4d78-93ac-9f3288a63bae.pdf) |
| from bse | [Annual Report 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/543434/74546543434.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:22:21.124Z.